Last reviewed · How we verify

NCT04738539

Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies

Status unknown Last updated 28 April 2021
What this trial tests

trial testing Contrast Enhanced Voiding Urosonography with Urodynamic Testing in Myelomeningocele in 105 participants. Status unknown.

Timeline
2 March 2021
Primary endpoint
2 March 2022
2 March 2022

Quick facts

Lead sponsorUniversity of Virginia
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment105
Start date2 March 2021
Primary completion2 March 2022
Estimated completion2 March 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Virginia

Who can join

Under 18, any sex, with Myelomeningocele or Neurogenic Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myelomeningocele

Currently open trials in the same condition.

Other University of Virginia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04738539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing